Evolent Health price target lowered to $41 from $44 at Canaccord
The Fly

Evolent Health price target lowered to $41 from $44 at Canaccord

Canaccord lowered the firm’s price target on Evolent Health to $41 from $44 and keeps a Buy rating on the shares. The firm said the company handily beat consensus revenue as well as above the high end of quarterly guide, with adjusted EBITDA coming roughly in line with Street estimates, slightly below the midpoint of prior quarterly guide while noting the company raised revenue guidance for the year.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App